HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Aldoxorubicin

HCID 9810709
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
1361644-26-9
Standard SMILES
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(/C(CO)=N/NC(=O)CCCCCN1C(=O)C=CC1=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
InChIKey
OBMJQRLIQQTJLR-USGQOSEYSA-N
Molecular formula
C37H42N4O13
Average molar mass
750.7 g/mol
Monoisotopic mass
750.27483741

Overview

Aldoxorubicin, an antineoplastic agents, is an albumin-binding prodrug of doxorubicin.

Names & identifiers

Preferred name
Aldoxorubicin
IUPAC
N-[(E)-[1-[(2S,4S)-4-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-hydroxyethylidene]amino]-6-(2,5-dioxopyrrol-1-yl)hexanamide
English name
INNO206
Molecular formula
C37H42N4O13
Molecular weight
750.75

Names & synonyms

ALDOXORUBICININNO-206Doxorubicin-EMCHaldoxorubicinealdoxorubicinaN-[(E)-[1-[(2S,4S)-4-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-hydroxyethylidene]amino]-6-(2,5-dioxopyrrol-1-yl)hexanamideC28MV4IM0BaldoxorubicinumN-((E)-(1-((2S,4S)-4-((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl)-2-hydroxyethylidene)amino)-6-(2,5-dioxopyrrol-1-yl)hexanamideRefChem:1106491H-Pyrrole-1-hexanoic acid, 2,5-dihydro-2,5-dioxo-, (1-(4-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl)-2-hydroxyethylidene)hydrazide, (2S-cis)-1361644-26-9
Show more names
Aldoxorubicin (INNO-206)Aldoxorubicin AldoxorubicinDoxorubicinImpurity16TrifluoroacetateN'-[(1E)-1-[(2S,4S)-4-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl]-2-hydroxyethylidene]-6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanehydrazide

Properties

Computed structural properties

XLogP
1.3
Topological polar surface area
268 Ų
Hydrogen bond donors
7
Hydrogen bond acceptors
15
Rotatable bonds
12
Heavy atoms
54
Formal charge
0
Complexity
1,510

Experimental & physicochemical properties

DrugsPharmaceuticals -> Listed in ZINC15

Physicochemical properties

Density
1.6 · 1.60±0.1 g/cm3(Predicted)
storage temp.
-80 °, · -80°, stored under nitrogen,unstable in solution, ready to use.
solubility
75 mg/mL · DMSO : 75 mg/mL (99.90 mM)
form
Solid
pka
7.36 · 7.36±0.60(Predicted)
color
Purple to purplish red
FDA UNII
28 MV4IM0B · C28MV4IM0B
NCI Drug Dictionary
aldoxorubicin
Symbol(GHS)
8 · GHS08
Signal word
Danger
Hazard statements
340 · H340-H350-H360

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Safety data

Signal word
Danger
Symbol(GHS)
GHS08
Hazard statements
H340-H350-H360

Chemistry & industry

Pharmacology

Mechanism of Action · 1 item

INNO-206 is the (6-Maleimidocaproyl) hydrazone of doxorubicin. INNO-206 is a prodrug of doxorubicin that binds endogenous albumin after administration. The bound doxorubicin is released in the acidic environment of the tumor cell through cleavage of an acid sensitive linker. In preclinical models, INNO-206 was superior to doxorubicin with regard to antitumor efficacy and toxicity.

Applications · 1 item

UsesAldoxorubicin (INNO-206) is an albumin-binding proagent of Doxorubicin (DNA topoisomerase II inhibitor), which is released from albumin under acidic conditions. Aldoxorubicin (INNO-206) has potent antitumor activities in various cancer cell lines and in murine tumor models.

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
1H-Pyrrole-1-hexanoic acid, 2,5-dihydro-2,5-dioxo-, (2E)-2-[1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-hydroxyethylidene]hydrazide
(E)-N’-[1-[(2S,4S)-4-[[(2R,4S,5S,6S)-4-Amino-5-hydroxy-6-methyl-2-tetrahydropyranyl]oxy]-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-2-tetracenyl]-2-hydroxyethylidene]-6-(2,5-dioxo-2,5-dihydro-1-pyrrolyl)hexanehydrazide
MFCD15146982N'-((E)-1-((2S,4S)-4-(((2R,4S,5S,6S)-4-Amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl)-2-hydroxyethylidene)-6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanehydrazideAldoxorubicin [USAN]adoxorubicinC37H42N4O13Aldoxorubicin hydrochloridALDOXORUBICIN [INN]Aldoxorubicin (USAN/INN)

Database identifiers

CAS
1361644-26-9
PubChem CID
9810709
DTXSID
DTXSID001098062
ChEMBL
CHEMBL2107818
UNII
C28MV4IM0B
Nikkaji
J2.017.217G